These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 22104593

  • 21. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L, Egevad L, Ekman P, Hellström M.
    Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
    Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB.
    Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Recker F, Kwiatkowski M.
    Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ, Roobol DW, Schröder FH.
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 34. Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer.
    Kuller LH, Thomas A, Grandits G, Neaton JD, Multiple Risk Factor Intervention Trial Research Group.
    Cancer Epidemiol Biomarkers Prev; 2004 Mar 15; 13(3):373-7. PubMed ID: 15006911
    [Abstract] [Full Text] [Related]

  • 35. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, Köllermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK.
    Eur Urol; 2008 Apr 15; 53(4):750-7. PubMed ID: 17964070
    [Abstract] [Full Text] [Related]

  • 36. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study.
    Bohnen AM, Groeneveld FP, Bosch JL.
    Eur Urol; 2007 Jun 15; 51(6):1645-52; discussion 1652-3. PubMed ID: 17320271
    [Abstract] [Full Text] [Related]

  • 37. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
    Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, Knönagel H, Loidl W, Isorna S, Sundaram SK, Debois M, EORTC Genitourinary Group.
    Eur Urol; 2008 May 15; 53(5):941-9. PubMed ID: 18191322
    [Abstract] [Full Text] [Related]

  • 38. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A, Rhoden EL.
    Urology; 2006 Dec 15; 68(6):1263-7. PubMed ID: 17169647
    [Abstract] [Full Text] [Related]

  • 39. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
    Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA.
    N Engl J Med; 2004 May 27; 350(22):2239-46. PubMed ID: 15163773
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.